Lazard Asset Management LLC Immuno Gen, Inc. Transaction History

Lazard Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $78,186 - $187,936	-6,275 Reduced 32.34%	13,131 $389,000
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $273,430 - $385,597	19,406 New	19,406 $307,000
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $55,901 - $74,941	15,232 New	15,232 $58,000
Q2 2022 Aug 09, 2022	BUY	$3.15 - $5.76 $92,575 - $169,280	29,389 New	29,389 $132,000
Q4 2021 Feb 09, 2022	SELL	$4.75 - $7.5 $53,466 - $84,420	-11,256 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $56,505 - $74,177	11,256 New	11,256 $63,000
Q2 2021 Aug 12, 2021	SELL	$5.79 - $8.6 $33,622 - $49,940	-5,807 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$6.5 - $10.53 $37,745 - $61,147	5,807 New	5,807 $47,000
Q3 2018 Nov 13, 2018	SELL	$8.6 - $11.26 $635,178 - $831,641	-73,858 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$6.7 - $12.95 $105,672 - $204,247	15,772 Added 27.15%	73,858 $776,000
Q4 2017 Feb 13, 2018	BUY	$5.07 - $7.92 $294,496 - $460,041	58,086	58,086 $372,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.